Literature DB >> 20966311

Late gadolinium-enhanced cardiovascular MRI at end-systole: feasibility study.

Hidenari Matsumoto1, Tetsuya Matsuda, Kenichi Miyamoto, Toshihiko Shimada, Atsushi Hayashi, Mikiko Mikuri, Yuji Hiraoka.   

Abstract

OBJECTIVE: The purpose of this article is to evaluate the image quality and infarct size of segmented late gadolinium-enhanced cardiovascular MRI at end-systole, compared with middiastole, in patients with sinus rhythm (SR) and to compare the image quality of end-systole images in patients with atrial fibrillation (AFib) to that of end-systole and middiastole images in patients with SR. SUBJECTS AND METHODS: Study patients (n = 121) were distributed according to heart rate and rhythm: SR with low heart rate (≤ 65 beats/minute), SR with intermediate heart rate (66-75 beats/minute), SR with high heart rate (≥ 76 beats/minute), and AFib. Image quality was graded on a 5-point scale, where 4 equals optimal and 0 equals not assessable. Global infarct size (percentage of left ventricle [LV] myocardium) in patients with SR with myocardial infarction was quantified using a visual quantitative approach with a 5-point scale and a semiautomatic method.
RESULTS: End-systole imaging had higher image quality than did middiastole imaging for patients with SR with high heart rate, whereas middiastole imaging had higher image quality than did end-systole imaging for patients with SR with low heart rate (p < 0.05 for patients with SR with low heart rate, p = 0.60 for patients with SR with intermediate heart rate, and p = 0.001 for patients with SR with high heart rate). The quality of end-systole imaging in patients with AFib was not significantly different from that in patients with SR (p = 0.40 vs SR middiastole imaging and p = 0.38 vs SR end-systole imaging). The average difference of global infarct size was -0.3% and 0.2% of LV myocardium, and the limits of agreement were ± 2.4% and ± 3.3% of LV myocardium, for visual assessment and semiautomatic assessment, respectively.
CONCLUSION: End-systole imaging can provide accurate diagnosis of myocardial infarction, comparable to middiastole imaging. The image quality of end-systole imaging is less susceptible to heart rate and rhythm compared with middiastole imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20966311     DOI: 10.2214/AJR.09.3860

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  End-systolic versus end-diastolic late gadolinium enhanced imaging for the assessment of scar transmurality.

Authors:  Andreas Schuster; Amedeo Chiribiri; Masaki Ishida; Geraint Morton; Matthias Paul; Shazia Hussain; Boris Bigalke; Divaka Perera; Eike Nagel
Journal:  Int J Cardiovasc Imaging       Date:  2011-04-24       Impact factor: 2.357

2.  Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine.

Authors:  Moritz Wagner; Rene Schilling; Patrick Doeblin; Alexander Huppertz; Reny Luhur; Carsten Schwenke; Martin Maurer; Bernd Hamm; Matthias Taupitz; Tahir Durmus
Journal:  Eur Radiol       Date:  2012-07-08       Impact factor: 5.315

3.  Late iodine enhancement computed tomography with image subtraction for assessment of myocardial infarction.

Authors:  Yuki Tanabe; Teruhito Kido; Akira Kurata; Takanori Kouchi; Naoki Fukuyama; Takahiro Yokoi; Teruyoshi Uetani; Natsumi Yamashita; Masao Miyagawa; Teruhito Mochizuki
Journal:  Eur Radiol       Date:  2017-09-19       Impact factor: 5.315

4.  Functional LGE Imaging: Cardiac Phase-Resolved Assessment of Focal Fibrosis.

Authors:  Sebastian Weingartner; Omer Burak Demirel; Chetan Shenoy; Lothar R Schad; Jeanette Schulz-Menger; Mehmet Akcakaya
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2019-07

5.  Cardiac phase-resolved late gadolinium enhancement imaging.

Authors:  Sebastian Weingärtner; Ömer B Demirel; Francisco Gama; Iain Pierce; Thomas A Treibel; Jeanette Schulz-Menger; Mehmet Akçakaya
Journal:  Front Cardiovasc Med       Date:  2022-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.